Global Influenzavirus B Infection Drug Market Insights, Forecast to 2025

Table of Contents

1 Study Coverage

• 1.1 Influenzavirus B Infection Drug Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global Influenzavirus B Infection Drug Market Size Growth Rate by Product
  • 1.4.2 APP-309
  • 1.4.3 CF-403
  • 1.4.4 GC-3106A
  • 1.4.5 KIN-1400
  • 1.4.6 Others
• 1.5 Market by End User
  • 1.5.1 Global Influenzavirus B Infection Drug Market Size Growth Rate by End User
  • 1.5.2 Clinic
  • 1.5.3 Hospital
  • 1.5.4 Others
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Influenzavirus B Infection Drug Market Size
  • 2.1.1 Global Influenzavirus B Infection Drug Revenue 2014-2025
  • 2.1.2 Global Influenzavirus B Infection Drug Sales 2014-2025
• 2.2 Influenzavirus B Infection Drug Growth Rate by Regions
  • 2.2.1 Global Influenzavirus B Infection Drug Sales by Regions
  • 2.2.2 Global Influenzavirus B Infection Drug Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 Influenzavirus B Infection Drug Sales by Manufacturers
  • 3.1.1 Influenzavirus B Infection Drug Sales by Manufacturers
  • 3.1.2 Influenzavirus B Infection Drug Sales Market Share by Manufacturers
  • 3.1.3 Global Influenzavirus B Infection Drug Market Concentration Ratio (CR5 and HHI)
• 3.2 Influenzavirus B Infection Drug Revenue by Manufacturers
  • 3.2.1 Influenzavirus B Infection Drug Revenue by Manufacturers (2014-2019)
  • 3.2.2 Influenzavirus B Infection Drug Revenue Share by Manufacturers (2014-2019)
• 3.3 Influenzavirus B Infection Drug Price by Manufacturers
• 3.4 Influenzavirus B Infection Drug Manufacturing Base Distribution, Product Types
  • 3.4.1 Influenzavirus B Infection Drug Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Influenzavirus B Infection Drug Product Type
  • 3.4.3 Date of International Manufacturers Enter into Influenzavirus B Infection Drug Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global Influenzavirus B Infection Drug Sales by Product
• 4.2 Global Influenzavirus B Infection Drug Revenue by Product
• 4.3 Influenzavirus B Infection Drug Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global Influenzavirus B Infection Drug Breakdown Data by End User

6 North America

• 6.1 North America Influenzavirus B Infection Drug by Countries
  • 6.1.1 North America Influenzavirus B Infection Drug Sales by Countries
  • 6.1.2 North America Influenzavirus B Infection Drug Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America Influenzavirus B Infection Drug by Product
• 6.3 North America Influenzavirus B Infection Drug by End User

7 Europe

• 7.1 Europe Influenzavirus B Infection Drug by Countries
  • 7.1.1 Europe Influenzavirus B Infection Drug Sales by Countries
  • 7.1.2 Europe Influenzavirus B Infection Drug Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Influenzavirus B Infection Drug by Product
• 7.3 Europe Influenzavirus B Infection Drug by End User

8 Asia Pacific

• 8.1 Asia Pacific Influenzavirus B Infection Drug by Countries
  • 8.1.1 Asia Pacific Influenzavirus B Infection Drug Sales by Countries
  • 8.1.2 Asia Pacific Influenzavirus B Infection Drug Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific Influenzavirus B Infection Drug by Product
• 8.3 Asia Pacific Influenzavirus B Infection Drug by End User

9 Central & South America

• 9.1 Central & South America Influenzavirus B Infection Drug by Countries
  • 9.1.1 Central & South America Influenzavirus B Infection Drug Sales by Countries
  • 9.1.2 Central & South America Influenzavirus B Infection Drug Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America Influenzavirus B Infection Drug by Product
• 9.3 Central & South America Influenzavirus B Infection Drug by End User

10 Middle East and Africa

• 10.1 Middle East and Africa Influenzavirus B Infection Drug by Countries
  • 10.1.1 Middle East and Africa Influenzavirus B Infection Drug Sales by Countries
  • 10.1.2 Middle East and Africa Influenzavirus B Infection Drug Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa Influenzavirus B Infection Drug by Product
• 10.3 Middle East and Africa Influenzavirus B Infection Drug by End User

11 Company Profiles

• 11.1 AbbVie Inc
  • 11.1.1 AbbVie Inc Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 AbbVie Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 AbbVie Inc Influenzavirus B Infection Drug Products Offered
  • 11.1.5 AbbVie Inc Recent Development
• 11.2 Adimmune Corp
  • 11.2.1 Adimmune Corp Company Details
  • 11.2.2 Company Business Overview
  • 11.2.3 Adimmune Corp Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.2.4 Adimmune Corp Influenzavirus B Infection Drug Products Offered
  • 11.2.5 Adimmune Corp Recent Development
• 11.3 Altravax Inc
  • 11.3.1 Altravax Inc Company Details
  • 11.3.2 Company Business Overview
  • 11.3.3 Altravax Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.3.4 Altravax Inc Influenzavirus B Infection Drug Products Offered
  • 11.3.5 Altravax Inc Recent Development
• 11.4 Amarillo Biosciences Inc
  • 11.4.1 Amarillo Biosciences Inc Company Details
  • 11.4.2 Company Business Overview
  • 11.4.3 Amarillo Biosciences Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.4.4 Amarillo Biosciences Inc Influenzavirus B Infection Drug Products Offered
  • 11.4.5 Amarillo Biosciences Inc Recent Development
• 11.5 Aphios Corp
  • 11.5.1 Aphios Corp Company Details
  • 11.5.2 Company Business Overview
  • 11.5.3 Aphios Corp Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.5.4 Aphios Corp Influenzavirus B Infection Drug Products Offered
  • 11.5.5 Aphios Corp Recent Development
• 11.6 BioCryst Pharmaceuticals Inc
  • 11.6.1 BioCryst Pharmaceuticals Inc Company Details
  • 11.6.2 Company Business Overview
  • 11.6.3 BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.6.4 BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Products Offered
  • 11.6.5 BioCryst Pharmaceuticals Inc Recent Development
• 11.7 Cadila Healthcare Ltd
  • 11.7.1 Cadila Healthcare Ltd Company Details
  • 11.7.2 Company Business Overview
  • 11.7.3 Cadila Healthcare Ltd Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.7.4 Cadila Healthcare Ltd Influenzavirus B Infection Drug Products Offered
  • 11.7.5 Cadila Healthcare Ltd Recent Development
• 11.8 ContraFect Corp
  • 11.8.1 ContraFect Corp Company Details
  • 11.8.2 Company Business Overview
  • 11.8.3 ContraFect Corp Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.8.4 ContraFect Corp Influenzavirus B Infection Drug Products Offered
  • 11.8.5 ContraFect Corp Recent Development
• 11.9 Daiichi Sankyo Company Ltd
  • 11.9.1 Daiichi Sankyo Company Ltd Company Details
  • 11.9.2 Company Business Overview
  • 11.9.3 Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.9.4 Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Products Offered
  • 11.9.5 Daiichi Sankyo Company Ltd Recent Development
• 11.10 Fujifilm Holdings Corporation
  • 11.10.1 Fujifilm Holdings Corporation Company Details
  • 11.10.2 Company Business Overview
  • 11.10.3 Fujifilm Holdings Corporation Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.10.4 Fujifilm Holdings Corporation Influenzavirus B Infection Drug Products Offered
  • 11.10.5 Fujifilm Holdings Corporation Recent Development
• 11.11 GlaxoSmithKline Plc
• 11.12 Green Cross Corp
• 11.13 Inovio Pharmaceuticals Inc
• 11.14 Kineta Inc
• 11.15 Medicago Inc
• 11.16 MedImmune LLC
• 11.17 Mucosis BV
• 11.18 Novavax Inc
• 11.19 Park Active Molecules
• 11.20 Romark Laboratories LC

12 Future Forecast

• 12.1 Influenzavirus B Infection Drug Market Forecast by Regions
  • 12.1.1 Global Influenzavirus B Infection Drug Sales Forecast by Regions 2019-2025
  • 12.1.2 Global Influenzavirus B Infection Drug Revenue Forecast by Regions 2019-2025
• 12.2 Influenzavirus B Infection Drug Market Forecast by Product
  • 12.2.1 Global Influenzavirus B Infection Drug Sales Forecast by Product 2019-2025
  • 12.2.2 Global Influenzavirus B Infection Drug Revenue Forecast by Product 2019-2025
• 12.3 Influenzavirus B Infection Drug Market Forecast by End User
• 12.4 North America Influenzavirus B Infection Drug Forecast
• 12.5 Europe Influenzavirus B Infection Drug Forecast
• 12.6 Asia Pacific Influenzavirus B Infection Drug Forecast
• 12.7 Central & South America Influenzavirus B Infection Drug Forecast
• 12.8 Middle East and Africa Influenzavirus B Infection Drug Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Influenzavirus B Infection Drug Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details